Search the Newsreel

Alpha Tau Medical (DRTS) Clinical Progress Tests Whether The Stock Already Looks Fully Valued

Alpha Tau Medical (DRTS) has reported a wider net loss for the first half of 2026, despite significant clinical and partnership milestones. The stock has seen a substantial price surge, with a 195.45% year-to-date return, reflecting strong investor confidence in its future potential. However, …

Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 5.4% Following Insider Selling

Alpha Tau Medical (NASDAQ:DRTS) shares dropped 5.4% after CFO Raphi Levy sold 17,730 shares, reducing his position by over 16%. Despite the sell-off, analyst sentiment remains "Moderate Buy" with an average price target that is currently below the recent share price. The company also …

Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $248,220.00 in Stock

Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy sold 17,730 shares of the company's stock for $248,220 at an average price of $14.00, reducing his direct holdings by 16.43%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan and follows several other sales …

Five Takeaways from AHNS 2026: Alpha DaRT in Combination with Immunotherapy for Advanced Head and Neck Cancer

This article discusses key takeaways from AHNS 2026 regarding the combination of Alpha DaRT with immunotherapy for advanced head and neck cancer. It highlights a shift in focus from new drug discovery to optimizing existing immunotherapy treatments. The study, though small, showed promising results …

H.C. Wainwright raises Alpha Tau Medical stock price target to $16

H.C. Wainwright has increased its price target for Alpha Tau Medical Ltd. (NASDAQ:DRTS) to $16.00 from $15.00, maintaining a Buy rating. This adjustment follows the company's significant progress in multiple cancer indications and its stock's 339% gain over the past year. Alpha Tau Medical …

Preferred dividends of Alpha Tau Medical Ltd – TASE:DRTS

This article provides financial information for Alpha Tau Medical Ltd (TASE:DRTS) on TradingView, specifically focusing on preferred dividends. It details market data, reference data, and legal disclaimers related to the company's financial reporting. The content is concise, indicating a lack of specific dividend values …

Free cash flow per share of Alpha Tau Medical Ltd – TASE:DRTS

This article focuses on the free cash flow per share of Alpha Tau Medical Ltd, traded on the Tel Aviv Stock Exchange under the ticker DRTS. It appears to be a data-driven page from TradingView, presenting financial information for the company. The content primarily …

Price to sales ratio of Alpha Tau Medical Ltd – TASE:DRTS

This page provides information on the price-to-sales ratio for Alpha Tau Medical Ltd (TASE:DRTS) as listed on the Tel Aviv Stock Exchange. It appears to be a financial data presentation page from TradingView, focusing on the company's financial metrics. The specific value and change …

Alpha Tau Medical (NASDAQ:DRTS) Hits New 12-Month High Following Analyst Upgrade

Alpha Tau Medical (NASDAQ:DRTS) reached a new 52-week high after HC Wainwright raised its price target to $16 with a "Buy" rating. Despite the positive analyst sentiment and an average "Moderate Buy" rating, the company recently missed earnings estimates with a quarterly loss of …

HC Wainwright Issues Positive Forecast for Alpha Tau Medical (NASDAQ:DRTS) Stock Price

HC Wainwright has raised its price target for Alpha Tau Medical (NASDAQ:DRTS) from $15 to $16, reiterating a "buy" rating and suggesting an 18.43% upside. Despite this positive outlook and a "Moderate Buy" consensus from analysts, the company recently reported a quarterly loss of …

Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Alpha Tau Medical Ltd. announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) in addition to Nasdaq, making its shares available to Israeli investors in local currency and business hours. This move follows growing interest from the Israeli …

Alpha Tau Medical earnings missed by $0.12, revenue fell short of estimates

Alpha Tau Medical (NASDAQ: DRTS) reported Q2 EPS of $-0.250, missing analyst estimates by $0.12, and revenue of $100K, falling short of the $144.5K consensus. Despite the earnings miss, the company's stock has seen significant gains, rising 30.640% in the last 3 months and …

Alpha Tau Medical (NASDAQ:DRTS) Releases Earnings Results, Misses Estimates By $0.36 EPS

Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update

Alpha Tau Medical Ltd. reported its second-quarter 2026 financial results, highlighting significant clinical and corporate achievements. These include positive interim results from the REGAIN trial for recurrent glioblastoma, a strategic collaboration with Tolmar for prostate cancer, and the completion of patient enrollment for the …

Alpha Tau Medical (NASDAQ: DRTS) moves to dual-list shares on TASE

Alpha Tau Medical (NASDAQ: DRTS) announced its intention to dual-list its ordinary shares on the Tel Aviv Stock Exchange (TASE) alongside Nasdaq. The company has requested TASE registration for over 92 million outstanding shares, plus additional shares tied to existing and future equity incentives …

Alpha Tau Medical (DRTS) Earnings Date and Reports 2026 $DRTS

Alpha Tau Medical (NASDAQ:DRTS) Stock Rating Upgraded by Zacks Research

Zacks Research has upgraded Alpha Tau Medical (NASDAQ:DRTS) from a "strong sell" to a "hold" rating, though the broader analyst consensus remains a "Moderate Buy" with a target price of $12.60. The company's shares opened at $13.08, near their 52-week high, despite missing quarterly …

Alpha Tau Medical (DRTS) Expected to Post Earnings on Monday

Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial

Alpha Tau Medical (DRTS) shares dropped 5.7% despite reporting positive early-stop data from a single-center trial for its Alpha DaRT device combined with pembrolizumab. The trial achieved a 100% objective response rate in elderly patients with head and neck squamous cell carcinoma, highlighting the …

Alpha Tau’s Cancer Combination Just Delivered a Response Rate More Than 5X Keytruda’s Historical Benchmar

Alpha Tau Medical Ltd. has reported promising results for its Alpha DaRT-pembrolizumab combination therapy for head and neck cancer, achieving a 100% objective response rate in a small study of nine evaluable patients. This significantly outperforms Keytruda's historical benchmark of 19% in similar patients. …

DRTS|Alpha Tau Medical Ltd|Price:11.600|Chg%:-0.610

This article provides a detailed financial overview of Alpha Tau Medical Ltd (DRTS), including its latest stock price, market capitalization, and key financial indicators. It presents quarterly and annual data for EPS, Net Profit, Debt-to-assets ratio, Income Statement, Balance Sheet, and Cash Flow Statement, …

Alpha Tau Medical Ltd. (DRTS) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures Shares - Forward Guidance Trends

Alpha Tau Medical Ltd. Revenue Breakdown – NASDAQ:DRTSW

This article provides details on Alpha Tau Medical Ltd. (NASDAQ:DRTSW) financials, specifically focusing on its revenue breakdown. It highlights where to find financial statements, statistics, dividends, earnings, and segment information, categorized by source and country. The information is sourced from FactSet Research Systems Inc. …

Alpha Tau Medical (DRTS) Clinical Win Puts Its Pricey Valuation Back In Focus

Alpha Tau Medical (DRTS) is gaining attention after reporting a 100% objective response rate for its Alpha DaRT regimen in elderly head and neck cancer patients, despite a recent stock pullback. The company's valuation, evidenced by a high price-to-book ratio of 16.3x, suggests high …

Alpha Tau Medical Ltd (DRTS) Cash Flow

This article provides a detailed cash flow statement for Alpha Tau Medical Ltd (DRTS), breaking down operating, investing, and financing cash flows on both a quarterly and annual basis. It includes specific financial figures for different periods and offers explanations of key cash flow …

DRTS|Alpha Tau Medical Ltd|Price:12.690|

This article provides details about Alpha Tau Medical Ltd (DRTS), including its stock price, market cap, and a disclaimer that no stock score is available due to insufficient data. It also explains how TradingKey calculates its comprehensive stock score based on 34 indicators across …

Alpha Tau Medical Ltd (DRTS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Alpha Tau Medical Ltd (DRTS), identifying major institutional and individual holders. It provides a breakdown of ownership percentages by type and lists recent changes in shareholdings for key investors. The data highlights Oramed Pharmaceuticals Inc. as the …

Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study

Alpha Tau Medical (DRTS) shares dropped 7.7% despite reporting a 100% objective response rate in its Alpha DaRT plus pembrolizumab study for head and neck squamous cell carcinoma. This positive clinical data strengthens the company's investment narrative for its Alpha DaRT therapy, although the …

Enterprise value to EBIT forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW

The article presents financial data for Alpha Tau Medical Ltd. (NASDAQ: DRTSW), specifically focusing on its enterprise value to EBIT forward. It indicates the stock is listed on the Nasdaq Stock Market and provides information within the context of TradingView's financial analysis tools.

Alpha Tau Medical Ltd. Revenue Breakdown – NASDAQ:DRTS

H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alpha Tau Medical (NASDAQ:DRTS) following positive clinical trial results for its Alpha DaRT therapy combined with pembrolizumab in head and neck cancer. The company also announced FDA clearance for further enrollment …

Alpha Tau rises on Alpha DaRT head and neck cancer data

Alpha Tau Medical (DRTS) stock rose approximately 5% in premarket trading after releasing new data on its Alpha DaRT therapy combined with Merck's Keytruda. The combination demonstrated a 100% objective response rate in nine evaluable head and neck cancer patients. This positive data indicates …

Alpha Tau reports positive trial results for cancer therapy combo

Alpha Tau Medical Ltd. announced positive results from a clinical study combining its Alpha DaRT therapy with pembrolizumab for elderly patients with head and neck squamous cell carcinoma. The study showed a 100% objective response rate and a median overall survival of 18.2 months, …